Total Payments
$106,126
2024 Payments
$4,150
Companies
7
Transactions
19
Medicare Patients
1,011
Medicare Billing
$177,809
Payment Breakdown by Category
Consulting$103,521 (97.5%)
Research$2,124 (2.0%)
Food & Beverage$329.13 (0.3%)
Other$151.86 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $103,521 | 10 | 97.5% |
| Unspecified | $2,124 | 4 | 2.0% |
| Food and Beverage | $329.13 | 4 | 0.3% |
| Entertainment | $151.86 | 1 | 0.1% |
Payments by Type
General
$104,002
15 transactions
Research
$2,124
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $99,371 | 7 | $0 (2017) |
| Beckman Coulter, Inc. | $2,400 | 1 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,287 | 6 | $0 (2019) |
| Merck Sharp & Dohme LLC | $1,750 | 2 | $0 (2024) |
| ZOLL Respicardia, Inc. | $152.48 | 1 | $0 (2023) |
| Resmed Corp | $151.86 | 1 | $0 (2017) |
| Maquet Cardiovascular U.S. Sales, L.L.C. | $13.24 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,150 | 3 | Beckman Coulter, Inc. ($2,400) |
| 2023 | $152.48 | 1 | ZOLL Respicardia, Inc. ($152.48) |
| 2020 | $13.24 | 1 | Maquet Cardiovascular U.S. Sales, L.L.C. ($13.24) |
| 2019 | $2,124 | 4 | NOVARTIS PHARMACEUTICALS CORPORATION ($2,124) |
| 2018 | $38.41 | 1 | Novartis Pharmaceuticals Corporation ($38.41) |
| 2017 | $99,648 | 9 | GlaxoSmithKline, LLC. ($99,371) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/10/2024 | Beckman Coulter, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 09/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 08/26/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 02/15/2023 | ZOLL Respicardia, Inc. | remede System (Device) | Food and Beverage | Cash or cash equivalent | $152.48 | General |
| Category: Respiratory | ||||||
| 01/14/2020 | Maquet Cardiovascular U.S. Sales, L.L.C. | CARDIOHELP (Device) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/10/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $837.88 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: CARDIOVASCULAR | ||||||
| 03/10/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $744.78 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: CARDIOVASCULAR | ||||||
| 03/10/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $286.50 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: CARDIOVASCULAR | ||||||
| 03/10/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | In-kind items and services | $254.67 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: CARDIOVASCULAR | ||||||
| 04/27/2018 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $38.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2017 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $26,157.50 | General |
| 09/27/2017 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $14,430.00 | General |
| 09/12/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $4,247.50 | General |
| Category: RESPIRATORY | ||||||
| 07/10/2017 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $23,161.25 | General |
| 05/21/2017 | Resmed Corp | ApneaLink (Device) | Entertainment | In-kind items and services | $151.86 | General |
| Category: Sleep | ||||||
| 04/14/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $9,502.50 | General |
| Category: RESPIRATORY | ||||||
| 01/27/2017 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $9,572.50 | General |
| 01/27/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/09/2017 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $12,300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,124 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 267 | 362 | $275,762 | $50,347 |
| 2022 | 9 | 282 | 372 | $239,027 | $47,697 |
| 2021 | 6 | 239 | 320 | $178,179 | $40,909 |
| 2020 | 6 | 223 | 312 | $168,359 | $38,856 |
Total Patients
1,011
Total Services
1,366
Medicare Billing
$177,809
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 50 | 95 | $86,545 | $16,420 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 56 | 82 | $30,258 | $7,242 | 23.9% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 12 | 12 | $38,940 | $6,577 | 16.9% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 11 | 11 | $39,270 | $6,371 | 16.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 52 | $18,460 | $5,030 | 27.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $21,242 | $4,555 | 21.4% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 13 | 19 | $7,712 | $1,654 | 21.4% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 21 | 21 | $20,652 | $1,312 | 6.4% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 32 | 32 | $12,683 | $1,185 | 9.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 51 | 110 | $90,501 | $19,509 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 65 | $23,985 | $6,217 | 25.9% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 11 | 11 | $35,695 | $5,923 | 16.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $20,683 | $4,448 | 21.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 54 | $19,170 | $4,354 | 22.7% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2022 | 28 | 28 | $23,660 | $2,449 | 10.3% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 20 | 26 | $10,036 | $2,354 | 23.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $5,148 | $1,230 | 23.9% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2022 | 30 | 30 | $10,149 | $1,214 | 12.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 45 | 106 | $85,432 | $19,340 | 22.6% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2021 | 38 | 38 | $22,985 | $5,969 | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 47 | 56 | $19,684 | $5,816 | 29.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 35 | 35 | $18,929 | $4,489 | 23.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 42 | $14,385 | $3,629 | 25.2% |
| 95806 | Unattended sleep study with recording of heart rate, oxygen, respiratory airflow and effort | Office | 2021 | 43 | 43 | $16,764 | $1,666 | 9.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 47 | 98 | $83,692 | $18,157 | 21.7% |
About Dr. Robert Owens, MD
Dr. Robert Owens, MD is a Pulmonary Disease healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972589265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Owens, MD has received a total of $106,126 in payments from pharmaceutical and medical device companies, with $4,150 received in 2024. These payments were reported across 19 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($103,521).
As a Medicare-enrolled provider, Owens has provided services to 1,011 Medicare beneficiaries, totaling 1,366 services with total Medicare billing of $177,809. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Sleep Medicine, Critical Care Medicine
- Location San Diego, CA
- Active Since 12/19/2005
- Last Updated 09/26/2017
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1972589265
Products in Payments
- NUCALA (Biological) $13,750
- ENTRESTO (Drug) $2,287
- remede System (Device) $152.48
- ApneaLink (Device) $151.86
- CARDIOHELP (Device) $13.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in San Diego
Dr. George Cheng, Md Phd, MD PHD
Pulmonary Disease — Payments: $230,134
Pulmonary Disease $230,134
Dr. Xuanha White, D.o, D.O
Pulmonary Disease — Payments: $216,172
Pulmonary Disease $216,172
Praveen Akuthota, M.d, M.D
Pulmonary Disease — Payments: $183,353
Pulmonary Disease $183,353
Wael El Maraachli, Md, MD
Pulmonary Disease — Payments: $114,418
Pulmonary Disease $114,418
Dr. Demosthenes Papamatheakis, Md, MD
Pulmonary Disease — Payments: $111,552
Pulmonary Disease $111,552
Dr. David Willms, M.d, M.D
Pulmonary Disease — Payments: $77,353
Pulmonary Disease $77,353